$CVEO
Civeo Corp

2023 Q2 Form 10-Q Financial Statement

#000159058423000075 Filed on April 28, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2023 Q1 2022 Q4
Revenue $178.8M $167.6M $162.2M
YoY Change -3.3% 1.15% 1.5%
Cost Of Revenue $131.4M $133.5M $127.5M
YoY Change 5.44% 9.9% 12.08%
Gross Profit $47.43M $34.11M $34.67M
YoY Change -21.37% -22.87% -24.65%
Gross Profit Margin 26.52% 20.35% 21.37%
Selling, General & Admin $16.47M $16.19M $19.54M
YoY Change -6.86% 6.42% 9.54%
% of Gross Profit 34.72% 47.46% 56.35%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $20.70M $21.66M $21.40M
YoY Change -10.32% 7.63% 6.06%
% of Gross Profit 43.65% 63.5% 61.72%
Operating Expenses $37.26M $16.19M $41.19M
YoY Change 110.7% 6.42% 7.84%
Operating Profit $10.17M -$3.904M -$6.525M
YoY Change -28.58% -192.14% -183.5%
Interest Expense -$3.554M $3.656M -$3.373M
YoY Change -236.27% 48.14% 11.14%
% of Operating Profit -34.94%
Other Income/Expense, Net $427.0K $2.450M $859.0K
YoY Change 2.89% 44.46% -87.96%
Pretax Income $7.045M -$5.078M -$14.76M
YoY Change -41.54% -246.55% -223.91%
Income Tax $2.878M $1.200M -$2.689M
% Of Pretax Income 40.85%
Net Earnings $4.463M -$6.353M -$13.00M
YoY Change -53.35% -550.57% -226.5%
Net Earnings / Revenue 2.5% -3.79% -8.02%
Basic Earnings Per Share $0.30 -$0.42
Diluted Earnings Per Share $0.30 -$0.42 -$0.94
COMMON SHARES
Basic Shares Outstanding 15.05M shares 15.22M shares 13.71M shares
Diluted Shares Outstanding 15.00M shares 15.16M shares

Balance Sheet

Concept 2023 Q2 2023 Q1 2022 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $11.42M $12.37M $7.954M
YoY Change 138.83% 92.53% 26.62%
Cash & Equivalents $11.42M $12.37M $7.954M
Short-Term Investments
Other Short-Term Assets $17.20M $2.594M $3.081M
YoY Change 173.73% -67.45% -71.85%
Inventory $7.171M $7.379M $6.907M
Prepaid Expenses $6.165M $5.138M $7.199M
Receivables $140.1M $123.0M $119.8M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $175.9M $158.6M $153.5M
YoY Change 3.63% -1.99% -2.32%
LONG-TERM ASSETS
Property, Plant & Equipment $289.6M $284.4M $301.9M
YoY Change -17.05% -26.33% -22.59%
Goodwill $7.522M $7.565M $7.672M
YoY Change -3.54% -10.66% -6.48%
Intangibles $80.64M $80.37M $81.75M
YoY Change -9.33% -14.08% -12.7%
Long-Term Investments
YoY Change
Other Assets $5.343M $5.176M $5.604M
YoY Change -3.73% -3.0% 4.32%
Total Long-Term Assets $383.1M $392.5M $412.6M
YoY Change -18.09% -23.22% -19.96%
TOTAL ASSETS
Total Short-Term Assets $175.9M $158.6M $153.5M
Total Long-Term Assets $383.1M $392.5M $412.6M
Total Assets $559.0M $551.2M $566.2M
YoY Change -12.31% -18.12% -15.84%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $47.76M $47.82M $51.09M
YoY Change 5.3% 1.3% 3.58%
Accrued Expenses $24.24M $21.31M $39.21M
YoY Change -14.3% -6.53% 16.82%
Deferred Revenue $3.097M $3.993M $991.0K
YoY Change -57.32% -70.66% -94.64%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $14.66M $21.49M $28.45M
YoY Change -50.92% -30.4% -6.96%
Total Short-Term Liabilities $102.7M $103.2M $128.3M
YoY Change -13.97% -13.37% -6.33%
LONG-TERM LIABILITIES
Long-Term Debt $121.0M $120.4M $102.5M
YoY Change -1.64% -16.96% -28.12%
Other Long-Term Liabilities $31.32M $17.45M $14.17M
YoY Change 122.62% -5.83% 2.86%
Total Long-Term Liabilities $152.3M $137.9M $116.7M
YoY Change 11.11% -15.7% -25.39%
TOTAL LIABILITIES
Total Short-Term Liabilities $102.7M $103.2M $128.3M
Total Long-Term Liabilities $152.3M $137.9M $116.7M
Total Liabilities $266.8M $259.0M $262.5M
YoY Change -2.58% -13.71% -15.22%
SHAREHOLDERS EQUITY
Retained Earnings -$940.0M -$940.2M -$930.1M
YoY Change 4.04% 3.09% 1.88%
Common Stock $1.627B $1.625B $1.625B
YoY Change 2.66% 2.65% 2.66%
Preferred Stock
YoY Change
Treasury Stock (at cost) $9.063M $9.063M $9.063M
YoY Change 0.0% 0.0% 12.58%
Treasury Stock Shares 366.7K shares
Shareholders Equity $292.2M $288.7M $300.1M
YoY Change
Total Liabilities & Shareholders Equity $559.0M $551.2M $566.2M
YoY Change -12.31% -18.12% -15.84%

Cashflow Statement

Concept 2023 Q2 2023 Q1 2022 Q4
OPERATING ACTIVITIES
Net Income $4.463M -$6.353M -$13.00M
YoY Change -53.35% -550.57% -226.5%
Depreciation, Depletion And Amortization $20.70M $21.66M $21.40M
YoY Change -10.32% 7.63% 6.06%
Cash From Operating Activities $19.40M $358.0K $29.40M
YoY Change -10.49% -81.67% 16.24%
INVESTING ACTIVITIES
Capital Expenditures $6.945M $4.772M $7.955M
YoY Change 37.39% 32.85% -234.24%
Acquisitions
YoY Change
Other Investing Activities $454.0K $0.00 $4.311M
YoY Change -51.6% -100.0% -41.11%
Cash From Investing Activities -$6.491M -$2.507M -$3.644M
YoY Change 57.66% 141.52% -361.41%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net $7.389M
YoY Change -7.67%
Cash From Financing Activities -13.49M $6.570M -26.55M
YoY Change -27.28% -588.48% 4.47%
NET CHANGE
Cash From Operating Activities 19.40M $358.0K 29.40M
Cash From Investing Activities -6.491M -$2.507M -3.644M
Cash From Financing Activities -13.49M $6.570M -26.55M
Net Change In Cash -577.0K $4.412M -794.0K
YoY Change -41.6% 3029.08% -162.37%
FREE CASH FLOW
Cash From Operating Activities $19.40M $358.0K $29.40M
Capital Expenditures $6.945M $4.772M $7.955M
Free Cash Flow $12.46M -$4.414M $21.45M
YoY Change -25.06% 169.31% -31.3%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001590584
CY2023Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q1 dei Amendment Flag
AmendmentFlag
false
CY2023Q1 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
P9M
CY2023Q1 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
P1Y
CY2023Q1 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
P1Y
CY2023Q1 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
CY2023Q1 dei Document Type
DocumentType
10-Q
CY2023Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q1 dei Document Period End Date
DocumentPeriodEndDate
2023-03-31
CY2023Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q1 dei Entity File Number
EntityFileNumber
001-36246
CY2023Q1 dei Entity Registrant Name
EntityRegistrantName
Civeo Corp
CY2023Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
A1
CY2023Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
98-1253716
CY2023Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
Three Allen Center
CY2023Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
333 Clay Street
CY2023Q1 dei Entity Address Address Line3
EntityAddressAddressLine3
Suite 4980
CY2023Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
77002
CY2023Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Houston
CY2023Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
TX
CY2023Q1 dei City Area Code
CityAreaCode
713
CY2023Q1 dei Local Phone Number
LocalPhoneNumber
510-2400
CY2023Q1 dei Security12b Title
Security12bTitle
Common Shares, no par value
CY2023Q1 dei Trading Symbol
TradingSymbol
CVEO
CY2023Q1 dei Security Exchange Name
SecurityExchangeName
NYSE
CY2023Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q1 dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2023Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023Q1 dei Entity Small Business
EntitySmallBusiness
false
CY2023Q1 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
15049360 shares
CY2023Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
167591000 usd
CY2022Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
165678000 usd
CY2023Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
16190000 usd
CY2022Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
15213000 usd
CY2023Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
21662000 usd
CY2022Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
20127000 usd
CY2023Q1 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
-129000 usd
CY2022Q1 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
-258000 usd
CY2023Q1 us-gaap Costs And Expenses
CostsAndExpenses
171495000 usd
CY2022Q1 us-gaap Costs And Expenses
CostsAndExpenses
161441000 usd
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-3904000 usd
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
4237000 usd
CY2023Q1 us-gaap Interest Expense
InterestExpense
3656000 usd
CY2022Q1 us-gaap Interest Expense
InterestExpense
2468000 usd
CY2023Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
32000 usd
CY2022Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
0 usd
CY2023Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2450000 usd
CY2022Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1696000 usd
CY2023Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-5078000 usd
CY2022Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
3465000 usd
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1233000 usd
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1557000 usd
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-6311000 usd
CY2022Q1 us-gaap Profit Loss
ProfitLoss
1908000 usd
CY2023Q1 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
42000 usd
CY2022Q1 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
498000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-6353000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
1410000 usd
CY2023Q1 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
0 usd
CY2022Q1 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
487000 usd
CY2023Q1 us-gaap Net Income Loss From Continuing Operations Available To Common Shareholders Basic
NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic
-6353000 usd
CY2022Q1 us-gaap Net Income Loss From Continuing Operations Available To Common Shareholders Basic
NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic
923000 usd
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.42
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.06
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.42
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.06
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
15158000 shares
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
14096000 shares
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
15158000 shares
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
14219000 shares
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-6311000 usd
CY2022Q1 us-gaap Profit Loss
ProfitLoss
1908000 usd
CY2022Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax
OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
0 usd
CY2023Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax
OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
0 usd
CY2022Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax
OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
0 usd
CY2023Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax
OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
0 usd
CY2023Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-2176000 usd
CY2022Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
8012000 usd
CY2023Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-2176000 usd
CY2022Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
8012000 usd
CY2023Q1 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-8487000 usd
CY2022Q1 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
9920000 usd
CY2023Q1 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
40000 usd
CY2022Q1 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
538000 usd
CY2023Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-8527000 usd
CY2022Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
9382000 usd
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
12366000 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
7954000 usd
CY2023Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
122962000 usd
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
119755000 usd
CY2023Q1 us-gaap Inventory Net
InventoryNet
7379000 usd
CY2022Q4 us-gaap Inventory Net
InventoryNet
6907000 usd
CY2023Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
5138000 usd
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
7199000 usd
CY2023Q1 us-gaap Other Assets Current
OtherAssetsCurrent
2594000 usd
CY2022Q4 us-gaap Other Assets Current
OtherAssetsCurrent
3081000 usd
CY2023Q1 us-gaap Assets Of Disposal Group Including Discontinued Operation Current
AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
8184000 usd
CY2022Q4 us-gaap Assets Of Disposal Group Including Discontinued Operation Current
AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
8653000 usd
CY2023Q1 us-gaap Assets Current
AssetsCurrent
158623000 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
153549000 usd
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
284371000 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
301890000 usd
CY2023Q1 us-gaap Goodwill
Goodwill
7565000 usd
CY2022Q4 us-gaap Goodwill
Goodwill
7672000 usd
CY2023Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
80369000 usd
CY2022Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
81747000 usd
CY2023Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
15059000 usd
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
15722000 usd
CY2023Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
5176000 usd
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
5604000 usd
CY2023Q1 us-gaap Assets
Assets
551163000 usd
CY2022Q4 us-gaap Assets
Assets
566184000 usd
CY2023Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
47819000 usd
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
51087000 usd
CY2023Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
21309000 usd
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
39211000 usd
CY2023Q1 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
223000 usd
CY2022Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
178000 usd
CY2023Q1 us-gaap Long Term Debt Current
LongTermDebtCurrent
21485000 usd
CY2022Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
28448000 usd
CY2023Q1 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
3993000 usd
CY2022Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
991000 usd
CY2023Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
8387000 usd
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
8342000 usd
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
103216000 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
128257000 usd
CY2023Q1 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
120441000 usd
CY2022Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
102505000 usd
CY2023Q1 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
5874000 usd
CY2022Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
4778000 usd
CY2023Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
12005000 usd
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
12771000 usd
CY2023Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
17450000 usd
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
14172000 usd
CY2023Q1 us-gaap Liabilities
Liabilities
258986000 usd
CY2022Q4 us-gaap Liabilities
Liabilities
262483000 usd
CY2022Q4 us-gaap Preferred Stock No Par Value
PreferredStockNoParValue
0
CY2023Q1 us-gaap Preferred Stock No Par Value
PreferredStockNoParValue
0
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
50000000 shares
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
2400000 shares
CY2023Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
50000000 shares
CY2023Q1 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2022Q4 us-gaap Common Stock No Par Value
CommonStockNoParValue
0
CY2023Q1 us-gaap Common Stock No Par Value
CommonStockNoParValue
0
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
46000000 shares
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
46000000 shares
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
15416035 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
15584176 shares
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
15049360 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
15217501 shares
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
0 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
0 usd
CY2023Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1625379000 usd
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1624512000 usd
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-940247000 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-930123000 usd
CY2023Q1 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
366675 shares
CY2022Q4 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
366675 shares
CY2023Q1 us-gaap Treasury Stock Value
TreasuryStockValue
9063000 usd
CY2022Q4 us-gaap Treasury Stock Value
TreasuryStockValue
9063000 usd
CY2023Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-387361000 usd
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-385187000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
288708000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
300139000 usd
CY2023Q1 us-gaap Minority Interest
MinorityInterest
3469000 usd
CY2022Q4 us-gaap Minority Interest
MinorityInterest
3562000 usd
CY2023Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
292177000 usd
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
303701000 usd
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
551163000 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
566184000 usd
CY2021Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
363111000 usd
CY2022Q1 us-gaap Profit Loss
ProfitLoss
1908000 usd
CY2022Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
8012000 usd
CY2022Q1 us-gaap Minority Interest Decrease From Distributions To Noncontrolling Interest Holders
MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
70000 usd
CY2022Q1 us-gaap Dividends Preferred Stock
DividendsPreferredStock
0 usd
CY2022Q1 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
9000 usd
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
19000 usd
CY2022Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
372971000 usd
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
303701000 usd
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-6311000 usd
CY2023Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-2176000 usd
CY2023Q1 us-gaap Minority Interest Decrease From Distributions To Noncontrolling Interest Holders
MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
133000 usd
CY2023Q1 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
3771000 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
867000 usd
CY2023Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
292177000 usd
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-6311000 usd
CY2022Q1 us-gaap Profit Loss
ProfitLoss
1908000 usd
CY2023Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
21662000 usd
CY2022Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
20127000 usd
CY2023Q1 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
1189000 usd
CY2022Q1 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
1491000 usd
CY2023Q1 us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
867000 usd
CY2022Q1 us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
1032000 usd
CY2023Q1 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
2018000 usd
CY2022Q1 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
1489000 usd
CY2023Q1 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
-68000 usd
CY2022Q1 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
-20000 usd
CY2023Q1 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-589000 usd
CY2022Q1 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-686000 usd
CY2023Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
4298000 usd
CY2022Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
7142000 usd
CY2023Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
535000 usd
CY2022Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
623000 usd
CY2023Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-20075000 usd
CY2022Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-13697000 usd
CY2023Q1 us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
45000 usd
CY2022Q1 us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
59000 usd
CY2023Q1 us-gaap Increase Decrease In Other Operating Capital Net
IncreaseDecreaseInOtherOperatingCapitalNet
-9311000 usd
CY2022Q1 us-gaap Increase Decrease In Other Operating Capital Net
IncreaseDecreaseInOtherOperatingCapitalNet
379000 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
358000 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
1953000 usd
CY2023Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
4772000 usd
CY2022Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3592000 usd
CY2023Q1 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
2265000 usd
CY2022Q1 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
2364000 usd
CY2023Q1 us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
0 usd
CY2022Q1 us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
-190000 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-2507000 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1038000 usd
CY2023Q1 us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
48045000 usd
CY2022Q1 us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
94266000 usd
CY2023Q1 us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
30315000 usd
CY2022Q1 us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
86586000 usd
CY2023Q1 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
7389000 usd
CY2022Q1 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
8003000 usd
CY2023Q1 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
3771000 usd
CY2022Q1 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
9000 usd
CY2023Q1 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
0 usd
CY2022Q1 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
1013000 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
6570000 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-1345000 usd
CY2023Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-9000 usd
CY2022Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
571000 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
4412000 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
141000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
7954000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
6282000 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
12366000 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
6423000 usd
CY2023Q1 us-gaap Dividends Preferred Stock Paidinkind
DividendsPreferredStockPaidinkind
0 usd
CY2022Q1 us-gaap Dividends Preferred Stock Paidinkind
DividendsPreferredStockPaidinkind
487000 usd
CY2023Q1 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
2 segment
CY2023Q1 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
2 segment
CY2023Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
167591000 usd
CY2022Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
165678000 usd
CY2023Q1 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
130325000 usd
CY2023Q1 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
131509000 usd
CY2023Q1 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
101967000 usd
CY2023Q1 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
357336000 usd
CY2023Q1 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
721137000 usd
CY2023Q1 us-gaap Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
123325000 usd
CY2022Q4 us-gaap Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
120054000 usd
CY2023Q1 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
363000 usd
CY2022Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
299000 usd
CY2023Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
122962000 usd
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
119755000 usd
CY2023Q1 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
5994000 usd
CY2022Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
5538000 usd
CY2023Q1 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
0 usd
CY2022Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
0 usd
CY2023Q1 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
1385000 usd
CY2022Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
1369000 usd
CY2023Q1 us-gaap Inventory Net
InventoryNet
7379000 usd
CY2022Q4 us-gaap Inventory Net
InventoryNet
6907000 usd
CY2022Q4 us-gaap Accrual For Taxes Other Than Income Taxes Current
AccrualForTaxesOtherThanIncomeTaxesCurrent
2873000 usd
CY2023Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1216000 usd
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1980000 usd
CY2023Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1587121000 usd
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1590202000 usd
CY2023Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1302750000 usd
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1288312000 usd
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
284371000 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
301890000 usd
CY2023Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
16797000 usd
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
34358000 usd
CY2023Q1 us-gaap Accrual For Taxes Other Than Income Taxes Current
AccrualForTaxesOtherThanIncomeTaxesCurrent
3296000 usd
CY2023Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
21309000 usd
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
39211000 usd
CY2023Q1 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
3993000 usd
CY2022Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
991000 usd
CY2023Q1 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
2972000 usd
CY2022Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
0 usd
CY2023Q1 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
6965000 usd
CY2022Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
991000 usd
CY2023Q1 us-gaap Disposal Group Including Discontinued Operation Property Plant And Equipment
DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment
8184000 usd
CY2022Q4 us-gaap Disposal Group Including Discontinued Operation Property Plant And Equipment
DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment
8653000 usd
CY2023Q1 us-gaap Assets Of Disposal Group Including Discontinued Operation
AssetsOfDisposalGroupIncludingDiscontinuedOperation
8184000 usd
CY2022Q4 us-gaap Assets Of Disposal Group Including Discontinued Operation
AssetsOfDisposalGroupIncludingDiscontinuedOperation
8653000 usd
CY2023Q1 us-gaap Net Income Loss From Continuing Operations Available To Common Shareholders Basic
NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic
-6353000 usd
CY2022Q1 us-gaap Net Income Loss From Continuing Operations Available To Common Shareholders Basic
NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic
923000 usd
CY2023Q1 us-gaap Undistributed Earnings Loss Allocated To Participating Securities Basic
UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
0 usd
CY2022Q1 us-gaap Undistributed Earnings Loss Allocated To Participating Securities Basic
UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
138000 usd
CY2023Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-6353000 usd
CY2022Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
785000 usd
CY2023Q1 us-gaap Undistributed Earnings Loss Allocated To Participating Securities Diluted
UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted
0 usd
CY2022Q1 us-gaap Undistributed Earnings Loss Allocated To Participating Securities Diluted
UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted
-138000 usd
CY2023Q1 cveo Undistributed Earnings Loss Reallocated To Participating Securities Diluted
UndistributedEarningsLossReallocatedToParticipatingSecuritiesDiluted
0 usd
CY2022Q1 cveo Undistributed Earnings Loss Reallocated To Participating Securities Diluted
UndistributedEarningsLossReallocatedToParticipatingSecuritiesDiluted
137000 usd
CY2023Q1 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-6353000 usd
CY2022Q1 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
786000 usd
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
15158000 shares
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
14096000 shares
CY2023Q1 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
0 shares
CY2022Q1 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
123000 shares
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
15158000 shares
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
14219000 shares
CY2023Q1 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.42
CY2022Q1 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
0.06
CY2023Q1 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.42
CY2022Q1 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
0.06
CY2023Q1 us-gaap Treasury Stock Acquired Average Cost Per Share
TreasuryStockAcquiredAverageCostPerShare
22.33
CY2023Q1 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
142608000 usd
CY2022Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
132037000 usd
CY2023Q1 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
682000 usd
CY2022Q4 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
1084000 usd
CY2023Q1 us-gaap Long Term Debt
LongTermDebt
141926000 usd
CY2022Q4 us-gaap Long Term Debt
LongTermDebt
130953000 usd
CY2023Q1 us-gaap Long Term Debt Current
LongTermDebtCurrent
21485000 usd
CY2022Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
28448000 usd
CY2023Q1 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
120441000 usd
CY2022Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
102505000 usd
CY2023Q1 cveo Interest Coverage Ratio
InterestCoverageRatio
3.00
CY2022Q1 us-gaap Treasury Stock Acquired Average Cost Per Share
TreasuryStockAcquiredAverageCostPerShare
18.47
CY2023Q1 cveo Number Of Tax Jurisdictions
NumberOfTaxJurisdictions
3 jurisdiction
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1200000 usd
CY2023Q1 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.243
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1600000 usd
CY2022Q1 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.449
CY2023Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-2200000 usd
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-385200000 usd
CY2023Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-387400000 usd
CY2023Q1 us-gaap Translation Adjustment Functional To Reporting Currency Net Of Tax
TranslationAdjustmentFunctionalToReportingCurrencyNetOfTax
174000000 cad
CY2023Q1 us-gaap Translation Adjustment Functional To Reporting Currency Net Of Tax
TranslationAdjustmentFunctionalToReportingCurrencyNetOfTax
223000000 aud
CY2021Q3 cveo Stock Repurchase Program Authorized Amount Percentage
StockRepurchaseProgramAuthorizedAmountPercentage
0.050
CY2022Q3 cveo Stock Repurchase Program Authorized Amount Percentage
StockRepurchaseProgramAuthorizedAmountPercentage
0.050
CY2022Q3 us-gaap Stock Repurchase Program Number Of Shares Authorized To Be Repurchased
StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
685000 shares
CY2021Q3 us-gaap Stock Repurchase Program Number Of Shares Authorized To Be Repurchased
StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
715000 shares
CY2022Q3 us-gaap Stock Repurchase Program Period In Force1
StockRepurchaseProgramPeriodInForce1
P12M
CY2021Q3 us-gaap Stock Repurchase Program Period In Force1
StockRepurchaseProgramPeriodInForce1
P12M
CY2023Q1 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
3771000 usd
CY2022Q1 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
9000 usd
CY2023Q1 us-gaap Treasury Stock Shares Acquired
TreasuryStockSharesAcquired
168700 shares
CY2022Q1 us-gaap Treasury Stock Shares Acquired
TreasuryStockSharesAcquired
500 shares
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
300000 usd
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
400000 usd
CY2023Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
167591000 usd
CY2023Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
21662000 usd
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-3904000 usd
CY2023Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
4772000 usd
CY2023Q1 us-gaap Assets
Assets
551163000 usd
CY2022Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
165678000 usd
CY2022Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
20127000 usd
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
4237000 usd
CY2022Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3592000 usd
CY2022Q1 us-gaap Assets
Assets
673094000 usd

Files In Submission

Name View Source Status
cveo-20230331_pre.xml Edgar Link unprocessable
cveo-20230331_cal.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
0001590584-23-000075-index-headers.html Edgar Link pending
0001590584-23-000075-index.html Edgar Link pending
0001590584-23-000075.txt Edgar Link pending
0001590584-23-000075-xbrl.zip Edgar Link pending
cveo-20230331.htm Edgar Link pending
cveo-20230331.xsd Edgar Link pending
cveo03-30x2023exhibit321.htm Edgar Link pending
cveo-20230331_lab.xml Edgar Link unprocessable
cveo-20230331_def.xml Edgar Link unprocessable
cveo-20230331_htm.xml Edgar Link completed
cveo03-31x2023exhibit311.htm Edgar Link pending
cveo03-31x2023exhibit312.htm Edgar Link pending
cveo03-31x2023exhibit322.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
rbc-civeoxfirstamendment.htm Edgar Link pending
rbc-civeoxfirstamendment001.jpg Edgar Link pending
rbc-civeoxfirstamendment002.jpg Edgar Link pending
rbc-civeoxfirstamendment003.jpg Edgar Link pending
rbc-civeoxfirstamendment004.jpg Edgar Link pending
rbc-civeoxfirstamendment005.jpg Edgar Link pending
rbc-civeoxfirstamendment006.jpg Edgar Link pending
rbc-civeoxfirstamendment007.jpg Edgar Link pending
rbc-civeoxfirstamendment008.jpg Edgar Link pending
rbc-civeoxfirstamendment009.jpg Edgar Link pending
rbc-civeoxfirstamendment010.jpg Edgar Link pending
rbc-civeoxfirstamendment011.jpg Edgar Link pending
rbc-civeoxfirstamendment012.jpg Edgar Link pending
rbc-civeoxfirstamendment013.jpg Edgar Link pending
rbc-civeoxfirstamendment014.jpg Edgar Link pending
rbc-civeoxfirstamendment015.jpg Edgar Link pending
rbc-civeoxfirstamendment016.jpg Edgar Link pending
rbc-civeoxfirstamendment017.jpg Edgar Link pending
rbc-civeoxfirstamendment018.jpg Edgar Link pending
rbc-civeoxfirstamendment019.jpg Edgar Link pending
rbc-civeoxfirstamendment020.jpg Edgar Link pending
rbc-civeoxfirstamendment021.jpg Edgar Link pending
rbc-civeoxfirstamendment022.jpg Edgar Link pending
rbc-civeoxfirstamendment023.jpg Edgar Link pending
rbc-civeoxfirstamendment024.jpg Edgar Link pending
rbc-civeoxfirstamendment025.jpg Edgar Link pending
rbc-civeoxfirstamendment026.jpg Edgar Link pending
rbc-civeoxfirstamendment027.jpg Edgar Link pending
rbc-civeoxfirstamendment028.jpg Edgar Link pending
rbc-civeoxfirstamendment029.jpg Edgar Link pending
rbc-civeoxfirstamendment030.jpg Edgar Link pending
rbc-civeoxfirstamendment031.jpg Edgar Link pending
rbc-civeoxfirstamendment032.jpg Edgar Link pending
rbc-civeoxfirstamendment033.jpg Edgar Link pending
rbc-civeoxfirstamendment034.jpg Edgar Link pending
rbc-civeoxfirstamendment035.jpg Edgar Link pending
rbc-civeoxfirstamendment036.jpg Edgar Link pending
rbc-civeoxfirstamendment037.jpg Edgar Link pending
rbc-civeoxfirstamendment038.jpg Edgar Link pending
rbc-civeoxfirstamendment039.jpg Edgar Link pending
rbc-civeoxfirstamendment040.jpg Edgar Link pending
rbc-civeoxfirstamendment041.jpg Edgar Link pending
rbc-civeoxfirstamendment042.jpg Edgar Link pending
rbc-civeoxfirstamendment043.jpg Edgar Link pending
rbc-civeoxfirstamendment044.jpg Edgar Link pending
rbc-civeoxfirstamendment045.jpg Edgar Link pending
rbc-civeoxfirstamendment046.jpg Edgar Link pending
rbc-civeoxfirstamendment047.jpg Edgar Link pending
rbc-civeoxfirstamendment048.jpg Edgar Link pending
rbc-civeoxfirstamendment049.jpg Edgar Link pending
rbc-civeoxfirstamendment050.jpg Edgar Link pending
rbc-civeoxfirstamendment051.jpg Edgar Link pending
rbc-civeoxfirstamendment052.jpg Edgar Link pending
rbc-civeoxfirstamendment053.jpg Edgar Link pending
rbc-civeoxfirstamendment054.jpg Edgar Link pending
rbc-civeoxfirstamendment055.jpg Edgar Link pending
rbc-civeoxfirstamendment056.jpg Edgar Link pending
rbc-civeoxfirstamendment057.jpg Edgar Link pending
rbc-civeoxfirstamendment058.jpg Edgar Link pending
rbc-civeoxfirstamendment059.jpg Edgar Link pending
rbc-civeoxfirstamendment060.jpg Edgar Link pending
rbc-civeoxfirstamendment061.jpg Edgar Link pending
rbc-civeoxfirstamendment062.jpg Edgar Link pending
rbc-civeoxfirstamendment063.jpg Edgar Link pending
rbc-civeoxfirstamendment064.jpg Edgar Link pending
rbc-civeoxfirstamendment065.jpg Edgar Link pending
rbc-civeoxfirstamendment066.jpg Edgar Link pending
rbc-civeoxfirstamendment067.jpg Edgar Link pending
rbc-civeoxfirstamendment068.jpg Edgar Link pending
rbc-civeoxfirstamendment069.jpg Edgar Link pending
rbc-civeoxfirstamendment070.jpg Edgar Link pending
rbc-civeoxfirstamendment071.jpg Edgar Link pending
rbc-civeoxfirstamendment072.jpg Edgar Link pending
rbc-civeoxfirstamendment073.jpg Edgar Link pending
rbc-civeoxfirstamendment074.jpg Edgar Link pending
rbc-civeoxfirstamendment075.jpg Edgar Link pending
rbc-civeoxfirstamendment076.jpg Edgar Link pending
rbc-civeoxfirstamendment077.jpg Edgar Link pending
rbc-civeoxfirstamendment078.jpg Edgar Link pending
rbc-civeoxfirstamendment079.jpg Edgar Link pending
rbc-civeoxfirstamendment080.jpg Edgar Link pending
rbc-civeoxfirstamendment081.jpg Edgar Link pending
rbc-civeoxfirstamendment082.jpg Edgar Link pending
rbc-civeoxfirstamendment083.jpg Edgar Link pending
rbc-civeoxfirstamendment084.jpg Edgar Link pending
rbc-civeoxfirstamendment085.jpg Edgar Link pending
rbc-civeoxfirstamendment086.jpg Edgar Link pending
rbc-civeoxfirstamendment087.jpg Edgar Link pending
rbc-civeoxfirstamendment088.jpg Edgar Link pending
rbc-civeoxfirstamendment089.jpg Edgar Link pending
rbc-civeoxfirstamendment090.jpg Edgar Link pending
rbc-civeoxfirstamendment091.jpg Edgar Link pending
rbc-civeoxfirstamendment092.jpg Edgar Link pending
rbc-civeoxfirstamendment093.jpg Edgar Link pending
rbc-civeoxfirstamendment094.jpg Edgar Link pending
rbc-civeoxfirstamendment095.jpg Edgar Link pending
rbc-civeoxfirstamendment096.jpg Edgar Link pending
rbc-civeoxfirstamendment097.jpg Edgar Link pending
rbc-civeoxfirstamendment098.jpg Edgar Link pending
rbc-civeoxfirstamendment099.jpg Edgar Link pending
rbc-civeoxfirstamendment100.jpg Edgar Link pending
rbc-civeoxfirstamendment101.jpg Edgar Link pending
rbc-civeoxfirstamendment102.jpg Edgar Link pending
rbc-civeoxfirstamendment103.jpg Edgar Link pending
rbc-civeoxfirstamendment104.jpg Edgar Link pending
rbc-civeoxfirstamendment105.jpg Edgar Link pending
rbc-civeoxfirstamendment106.jpg Edgar Link pending
rbc-civeoxfirstamendment107.jpg Edgar Link pending
rbc-civeoxfirstamendment108.jpg Edgar Link pending
rbc-civeoxfirstamendment109.jpg Edgar Link pending
rbc-civeoxfirstamendment110.jpg Edgar Link pending
rbc-civeoxfirstamendment111.jpg Edgar Link pending
rbc-civeoxfirstamendment112.jpg Edgar Link pending
rbc-civeoxfirstamendment113.jpg Edgar Link pending
rbc-civeoxfirstamendment114.jpg Edgar Link pending
rbc-civeoxfirstamendment115.jpg Edgar Link pending
rbc-civeoxfirstamendment116.jpg Edgar Link pending
rbc-civeoxfirstamendment117.jpg Edgar Link pending
rbc-civeoxfirstamendment118.jpg Edgar Link pending
rbc-civeoxfirstamendment119.jpg Edgar Link pending
rbc-civeoxfirstamendment120.jpg Edgar Link pending
rbc-civeoxfirstamendment121.jpg Edgar Link pending
rbc-civeoxfirstamendment122.jpg Edgar Link pending
rbc-civeoxfirstamendment123.jpg Edgar Link pending
rbc-civeoxfirstamendment124.jpg Edgar Link pending
rbc-civeoxfirstamendment125.jpg Edgar Link pending
rbc-civeoxfirstamendment126.jpg Edgar Link pending
rbc-civeoxfirstamendment127.jpg Edgar Link pending
rbc-civeoxfirstamendment128.jpg Edgar Link pending
rbc-civeoxfirstamendment129.jpg Edgar Link pending
rbc-civeoxfirstamendment130.jpg Edgar Link pending
rbc-civeoxfirstamendment131.jpg Edgar Link pending
rbc-civeoxfirstamendment132.jpg Edgar Link pending
rbc-civeoxfirstamendment133.jpg Edgar Link pending
rbc-civeoxfirstamendment134.jpg Edgar Link pending
rbc-civeoxfirstamendment135.jpg Edgar Link pending
rbc-civeoxfirstamendment136.jpg Edgar Link pending
rbc-civeoxfirstamendment137.jpg Edgar Link pending
rbc-civeoxfirstamendment138.jpg Edgar Link pending
rbc-civeoxfirstamendment139.jpg Edgar Link pending
rbc-civeoxfirstamendment140.jpg Edgar Link pending
rbc-civeoxfirstamendment141.jpg Edgar Link pending
rbc-civeoxfirstamendment142.jpg Edgar Link pending
rbc-civeoxfirstamendment143.jpg Edgar Link pending
rbc-civeoxfirstamendment144.jpg Edgar Link pending
rbc-civeoxfirstamendment145.jpg Edgar Link pending
rbc-civeoxfirstamendment146.jpg Edgar Link pending
rbc-civeoxfirstamendment147.jpg Edgar Link pending
rbc-civeoxfirstamendment148.jpg Edgar Link pending
rbc-civeoxfirstamendment149.jpg Edgar Link pending
rbc-civeoxfirstamendment150.jpg Edgar Link pending
rbc-civeoxfirstamendment151.jpg Edgar Link pending
rbc-civeoxfirstamendment152.jpg Edgar Link pending
rbc-civeoxfirstamendment153.jpg Edgar Link pending
rbc-civeoxfirstamendment154.jpg Edgar Link pending
rbc-civeoxfirstamendment155.jpg Edgar Link pending
rbc-civeoxfirstamendment156.jpg Edgar Link pending
rbc-civeoxfirstamendment157.jpg Edgar Link pending
rbc-civeoxfirstamendment158.jpg Edgar Link pending
rbc-civeoxfirstamendment159.jpg Edgar Link pending
rbc-civeoxfirstamendment160.jpg Edgar Link pending
rbc-civeoxfirstamendment161.jpg Edgar Link pending
rbc-civeoxfirstamendment162.jpg Edgar Link pending
rbc-civeoxfirstamendment163.jpg Edgar Link pending
rbc-civeoxfirstamendment164.jpg Edgar Link pending
rbc-civeoxfirstamendment165.jpg Edgar Link pending
rbc-civeoxfirstamendment166.jpg Edgar Link pending
rbc-civeoxfirstamendment167.jpg Edgar Link pending
rbc-civeoxfirstamendment168.jpg Edgar Link pending
rbc-civeoxfirstamendment169.jpg Edgar Link pending
rbc-civeoxfirstamendment170.jpg Edgar Link pending
rbc-civeoxfirstamendment171.jpg Edgar Link pending
rbc-civeoxfirstamendment172.jpg Edgar Link pending
rbc-civeoxfirstamendment173.jpg Edgar Link pending
rbc-civeoxfirstamendment174.jpg Edgar Link pending
rbc-civeoxfirstamendment175.jpg Edgar Link pending
rbc-civeoxfirstamendment176.jpg Edgar Link pending
rbc-civeoxfirstamendment177.jpg Edgar Link pending
rbc-civeoxfirstamendment178.jpg Edgar Link pending
rbc-civeoxfirstamendment179.jpg Edgar Link pending
rbc-civeoxfirstamendment180.jpg Edgar Link pending
rbc-civeoxfirstamendment181.jpg Edgar Link pending
rbc-civeoxfirstamendment182.jpg Edgar Link pending
rbc-civeoxfirstamendment183.jpg Edgar Link pending
rbc-civeoxfirstamendment184.jpg Edgar Link pending
rbc-civeoxfirstamendment185.jpg Edgar Link pending
rbc-civeoxfirstamendment186.jpg Edgar Link pending
rbc-civeoxfirstamendment187.jpg Edgar Link pending
rbc-civeoxfirstamendment188.jpg Edgar Link pending
rbc-civeoxfirstamendment189.jpg Edgar Link pending
rbc-civeoxfirstamendment190.jpg Edgar Link pending
rbc-civeoxfirstamendment191.jpg Edgar Link pending
rbc-civeoxfirstamendment192.jpg Edgar Link pending
rbc-civeoxfirstamendment193.jpg Edgar Link pending
rbc-civeoxfirstamendment194.jpg Edgar Link pending
rbc-civeoxfirstamendment195.jpg Edgar Link pending
rbc-civeoxfirstamendment196.jpg Edgar Link pending
rbc-civeoxfirstamendment197.jpg Edgar Link pending
rbc-civeoxfirstamendment198.jpg Edgar Link pending
rbc-civeoxfirstamendment199.jpg Edgar Link pending
rbc-civeoxfirstamendment200.jpg Edgar Link pending
rbc-civeoxfirstamendment201.jpg Edgar Link pending
rbc-civeoxfirstamendment202.jpg Edgar Link pending
rbc-civeoxfirstamendment203.jpg Edgar Link pending
rbc-civeoxfirstamendment204.jpg Edgar Link pending
rbc-civeoxfirstamendment205.jpg Edgar Link pending
rbc-civeoxfirstamendment206.jpg Edgar Link pending
rbc-civeoxfirstamendment207.jpg Edgar Link pending
rbc-civeoxfirstamendment208.jpg Edgar Link pending
rbc-civeoxfirstamendment209.jpg Edgar Link pending
rbc-civeoxfirstamendment210.jpg Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending